Candel Therapeutics (CADL) News Today $5.79 -0.03 (-0.52%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$5.78 0.00 (-0.09%) As of 08/29/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CADL Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Candel Therapeutics, Inc. Announces Participation in Upcoming Investor ConferencesAugust 28 at 8:31 AM | quiverquant.comQCandel Therapeutics to Participate in Upcoming Investor Conferences in SeptemberAugust 28 at 8:05 AM | globenewswire.comCandel Therapeutics Extends Lease Agreement in NeedhamAugust 22, 2025 | msn.comCandel Therapeutics Advances with Promising Cancer TherapiesAugust 18, 2025 | tipranks.comCandel Therapeutics (NASDAQ:CADL) Posts Earnings Results, Beats Expectations By $0.08 EPSAugust 16, 2025 | marketbeat.comCandel Therapeutics secures RMAT for prostate cancer – ICYMIAugust 16, 2025 | proactiveinvestors.comCandel Therapeutics secures RMAT for prostate cancer – ICYMIAugust 16, 2025 | proactiveinvestors.comCandel Therapeutics Faces Uncertainty Despite FDA RMAT Designation for Prostate Cancer TreatmentAugust 16, 2025 | msn.comCandel Therapeutics reports Q2 EPS (9c) vs. (74c) last yearAugust 14, 2025 | msn.comCandel Therapeutics files $300M mixed securities shelfAugust 14, 2025 | msn.comCandel Therapeutics advances toward prostate cancer therapy filing after trial successAugust 14, 2025 | proactiveinvestors.comCandel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate HighlightsAugust 14, 2025 | globenewswire.comWith 44% stake, Candel Therapeutics, Inc. (NASDAQ:CADL) seems to have captured institutional investors' interestAugust 8, 2025 | finance.yahoo.comCandel Therapeutics (CADL) Projected to Post Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comCandel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Rating of "Buy" from BrokeragesAugust 5, 2025 | marketbeat.comCandel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | globenewswire.comCandel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409July 24, 2025 | proactiveinvestors.comCandel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic CancerJuly 24, 2025 | globenewswire.comResearch Analysts Offer Predictions for CADL Q2 EarningsJuly 14, 2025 | marketbeat.comCandel Therapeutics, Inc. Gains Inclusion in Multiple Russell Value ...July 11, 2025 | nasdaq.comCandel Therapeutics, Inc. (NASDAQ:CADL) Given Average Recommendation of "Buy" by BrokeragesJuly 11, 2025 | marketbeat.comCandel Therapeutics (NASDAQ:CADL) Upgraded to "Strong-Buy" at Brookline Capital ManagementJuly 11, 2025 | marketbeat.comCandel Therapeutics expands Russell Index presence following 2025 reconstitutionJuly 9, 2025 | proactiveinvestors.comCandel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 ReconstitutionJuly 9, 2025 | globenewswire.comEquities Analysts Set Expectations for CADL Q3 EarningsJuly 1, 2025 | marketbeat.comCandel Therapeutics (NASDAQ:CADL) Receives "Buy" Rating from HC WainwrightJune 30, 2025 | marketbeat.comCADL - Candel Therapeutics Inc Ownership - MorningstarJune 28, 2025 | morningstar.comMOne Candel Therapeutics Insider Raised Stake By 22% In Previous YearJune 27, 2025 | finance.yahoo.comCandel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - NasdaqJune 26, 2025 | nasdaq.com2025-06-24 | Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock | NDAQ:CADL | Press ReleaseJune 26, 2025 | stockhouse.comCandel Therapeutics Inc News (CADL) - Investing.comJune 26, 2025 | investing.comCandel Therapeutics Appoints Charles Schoch as Chief Financial Officer - NasdaqJune 24, 2025 | nasdaq.comCandel Therapeutics prices 3.2M shares at $4.67 in registered direct offeringJune 24, 2025 | msn.comCandel Therapeutics announces $15M direct offering to support CAN-2409 launch preparationsJune 24, 2025 | proactiveinvestors.comCandel Therapeutics Announces $15 million Registered Direct Offering of Common StockJune 24, 2025 | globenewswire.comCandel Sinks on New CFOJune 23, 2025 | baystreet.caCandel Therapeutics names Charles Schoch as CFO after interim tenureJune 23, 2025 | proactiveinvestors.comCandel Therapeutics Appoints Charles Schoch as Chief Financial OfficerJune 23, 2025 | globenewswire.comBank of America Corp DE Buys 44,952 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL)June 11, 2025 | marketbeat.comCandel Therapeutics adds biotech veteran Maha Radhakrishnan to BoardJune 6, 2025 | proactiveinvestors.comCandel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsJune 6, 2025 | globenewswire.comCandel Therapeutics, Inc. (CADL)’s CAN-2409 Advances with FDA RMAT Status for Localized Prostate CancerMay 30, 2025 | msn.comCandel Therapeutics (CADL) Stock Is Surging Wednesday: What's Going On?May 28, 2025 | benzinga.comCandel Therapeutics Stock Soars On FDA’s RMAT Designation For Prostate Cancer Therapy: Retail Considers It Good Long-Term BuyMay 28, 2025 | msn.comCandel Therapeutics get FDA's RMAT designation for prostate cancer therapyMay 28, 2025 | proactiveinvestors.comCandel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate CancerMay 28, 2025 | globenewswire.comCandel Therapeutics: CAN-2409's Promising Progress Deserves An UpgradeMay 27, 2025 | seekingalpha.comCandel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO PresentationMay 27, 2025 | globenewswire.comCandel’s phase 3 trial for prostate cancer therapy shows promiseMay 24, 2025 | investing.comCandel Therapeutics to Present Positive Phase 3 Clinical Trial Results of CAN-2409 for Prostate Cancer at ASCO 2025May 24, 2025 | nasdaq.com Get Candel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CADL Media Mentions By Week CADL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CADL News Sentiment▼1.381.09▲Average Medical News Sentiment CADL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CADL Articles This Week▼33▲CADL Articles Average Week Get the Latest News and Ratings for CADL and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Candel Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies EVO News Today TLRY News Today XERS News Today PGEN News Today ELVN News Today COLL News Today CVAC News Today PHVS News Today CALT News Today LENZ News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CADL) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
